iTeos Therapeutics S.A. (Gosselies, Belgium) raised $75 million in a series B round led by MPM Capital.
Also participating in the round were HBM Partners, 6 Dimensions Capital, Curative Ventures and SFPI as well as existing investors Fund+, Vives Louvain Technology Fund, Société Régionale d’Investissement de Wallonie (SRIW) and Pfizer Inc. (NYSE:PFE).
The cancer company is planning first-in-human trials of two candidates: EOS100850, which is an antagonist of adenosine A2A receptor (ADORA2A); and EOS884448, an inhibitor of T cell immunoreceptor with Ig and ITIM domains (TIGIT). The A2A program will be tested in solid tumors, and is due to enter the clinic next half, CEO Michel Detheux told BioCentury. Next year, iTeos will likely first test the TIGIT program in a hematological indication, he said.
MPM provided more than 50% of the round's cash. The firm's Ansbert Gadicke told BioCentury he does not expect iTeos to raise additional private capital, and will consider a NASDAQ listing (see "Iterating iTeos").